507 related articles for article (PubMed ID: 36171610)
21. [Cancer Vaccine Focused on Neoantigens].
Shindo Y; Hazama S; Nagano H
Gan To Kagaku Ryoho; 2019 Sep; 46(9):1367-1371. PubMed ID: 31530772
[TBL] [Abstract][Full Text] [Related]
22. Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy?
Wirth TC; Kühnel F
Front Immunol; 2017; 8():1848. PubMed ID: 29312332
[TBL] [Abstract][Full Text] [Related]
23. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines.
Blass E; Ott PA
Nat Rev Clin Oncol; 2021 Apr; 18(4):215-229. PubMed ID: 33473220
[TBL] [Abstract][Full Text] [Related]
24. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
25. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
26. Next generation approaches for tumor vaccination.
Patel A; Kaufman HL; Disis ML
Chin Clin Oncol; 2017 Apr; 6(2):19. PubMed ID: 28482672
[TBL] [Abstract][Full Text] [Related]
27. Shared neoantigens: ideal targets for off-the-shelf cancer immunotherapy.
Zhao W; Wu J; Chen S; Zhou Z
Pharmacogenomics; 2020 Jun; 21(9):637-645. PubMed ID: 32423288
[TBL] [Abstract][Full Text] [Related]
28. Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens.
Pan RY; Chung WH; Chu MT; Chen SJ; Chen HC; Zheng L; Hung SI
J Immunol Res; 2018; 2018():4325874. PubMed ID: 30662919
[TBL] [Abstract][Full Text] [Related]
29. Targeting Tumor Heterogeneity with Neoantigen-Based Cancer Vaccines.
Pounraj S; Chen S; Ma L; Mazzieri R; Dolcetti R; Rehm BHA
Cancer Res; 2024 Feb; 84(3):353-363. PubMed ID: 38055891
[TBL] [Abstract][Full Text] [Related]
30. Utilizing immunogenomic approaches to prioritize targetable neoantigens for personalized cancer immunotherapy.
Shah RK; Cygan E; Kozlik T; Colina A; Zamora AE
Front Immunol; 2023; 14():1301100. PubMed ID: 38149253
[TBL] [Abstract][Full Text] [Related]
31. Vaccines and immune checkpoint inhibitors: a promising combination strategy in gastrointestinal cancers.
Bashir B; Flickinger JC; Snook AE
Immunotherapy; 2021 May; 13(7):561-564. PubMed ID: 33724866
[TBL] [Abstract][Full Text] [Related]
32. Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cancer immunobiology.
Panni UY; Chen MY; Zhang F; Cullinan DR; Li L; James CA; Zhang X; Rogers S; Alarcon A; Baer JM; Zhang D; Gao F; Miller CA; Gong Q; Lim KH; DeNardo DG; Goedegebuure SP; Gillanders WE; Hawkins WG
Cancer Immunol Immunother; 2023 Aug; 72(8):2813-2827. PubMed ID: 37179276
[TBL] [Abstract][Full Text] [Related]
33. [Identification of neoantigens and development of antigen-specific immunotherapy].
Shinohara S; Takahashi Y; Demachi-Okamura A; Matsushita H
Rinsho Ketsueki; 2020; 61(9):1433-1439. PubMed ID: 33162546
[TBL] [Abstract][Full Text] [Related]
34. The Immunogenicity and Anti-tumor Efficacy of a Rationally Designed Neoantigen Vaccine for B16F10 Mouse Melanoma.
Zhang Y; Lin Z; Wan Y; Cai H; Deng L; Li R
Front Immunol; 2019; 10():2472. PubMed ID: 31749795
[TBL] [Abstract][Full Text] [Related]
35. Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma.
Zolkind P; Dunn GP; Lin T; Griffith M; Griffith OL; Uppaluri R
Oral Oncol; 2017 Aug; 71():169-176. PubMed ID: 27751760
[TBL] [Abstract][Full Text] [Related]
36. A proteogenomic approach to target neoantigens in solid tumors.
Verma A; Halder A; Marathe S; Purwar R; Srivastava S
Expert Rev Proteomics; 2020; 17(11-12):797-812. PubMed ID: 33491499
[TBL] [Abstract][Full Text] [Related]
37. Targeting neoantigens for cancer immunotherapy.
Zhao X; Pan X; Wang Y; Zhang Y
Biomark Res; 2021 Jul; 9(1):61. PubMed ID: 34321091
[TBL] [Abstract][Full Text] [Related]
38. The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.
Ward JP; Gubin MM; Schreiber RD
Adv Immunol; 2016; 130():25-74. PubMed ID: 26922999
[TBL] [Abstract][Full Text] [Related]
39. The perfect personalized cancer therapy: cancer vaccines against neoantigens.
Aurisicchio L; Pallocca M; Ciliberto G; Palombo F
J Exp Clin Cancer Res; 2018 Apr; 37(1):86. PubMed ID: 29678194
[TBL] [Abstract][Full Text] [Related]
40. Determinants for Neoantigen Identification.
Garcia-Garijo A; Fajardo CA; Gros A
Front Immunol; 2019; 10():1392. PubMed ID: 31293573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
